Research | Clinical Trials | Clinical Trial Details Page

Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

Conditions

Schizoaffective Disorder | Schizophrenia

What is the purpose of this trial?

This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.


Participation Guidelines

Age:
18 Years - 65 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.

Sponsor:
Stanley Medical Research Institute
Yale University
Dates:
February 2009
Last Updated:
August 10, 2010
Study HIC#:
0710003164

Clinicaltrials.gov ID: NCT00588731